site stats

Jim doherty sage therapeutics

WebPaul is a co-founder and board member of Sage Therapeutics (NASDAQ: SAGE) and a co-founder of Voyager Therapeutics (NASDAQ: VYGR) where he served as President, Chief Executive Officer. Dr. Paul is the former director of the Appel Alzheimer’s Disease Research Institute at Weill Cornell Medical College and is currently a Professor of Psychiatry and … Web15 sep. 2024 · SAGE-718, Sage’s first-in-class NMDA receptor PAM and lead neuropsychiatric drug candidate, is in development as a potential oral therapy for cognitive disorders associated with NMDA receptor dysfunction, potentially including Huntington’s disease (HD), Parkinson’s disease (PD) and Alzheimer’s disease (AD).

Biography of Jim Doherty - The Official Board

WebJim Doherty Chief Development Officer at SAGE Therapeutics Cambridge, Massachusetts, United States 1K followers 500+ connections Join to view profile SAGE … WebJim Doherty Senior Vice President, Research at SAGE Therapeutics Location: Cambridge, Massachusetts Add to My Lists more ClaimEmbed Export James Doherty … patrick lassalle https://ofnfoods.com

Sage Therapeutics Announces Presentation of Promising Results …

Web17 mrt. 2024 · Sage Therapeutics is part of the Manufacturing industry, and located in Massachusetts, United States. Sage Therapeutics Location 215 1st St, Cambridge, Massachusetts, 02142, United States Description Industry Pharmaceuticals Healthcare Discover more about Sage Therapeutics Saritha Talapala Work Experience and Education WebSage Therapeutics is a biopharmaceutical company developing novel therapies for brain health disorders with Depression, Neurology and Neuropsychiatric franchise programs. … Web24 feb. 2024 · Sage Therapeutics, Inc. ( NASDAQ: SAGE) Q4 2024 Earnings Conference Call February 24, 2024 8:00 AM ET Company Participants Helen Rubinstein - Director, IR Barry Greene - CEO Jim Doherty -... patrick lasserre

Sage Therapeutics, Inc. (NASDAQ:SAGE) Q4 2024 Earnings Call …

Category:Sage Therapeutics

Tags:Jim doherty sage therapeutics

Jim doherty sage therapeutics

Jim Doherty - Chief Development.. - Sage Therapeutics ZoomInfo

Web9 nov. 2024 · Sage Therapeutics Inc ( NASDAQ:SAGE) Q3 2024 Earnings Call dated Nov. 08, 2024. Corporate Participants: Helen Rubinstein — Director of Investor Relations Barry Greene — Chief Executive Officer Jeff Jonas — Chief Innovation Officer Chris Benecchi — Chief Business Officer Jim Doherty — Chief Development Officer Kimi Iguchi — Chief … Web15 sep. 2024 · SAGE-718, Sage’s first-in-class NMDA receptor PAM and lead neuropsychiatric drug candidate, is in development as a potential oral therapy for …

Jim doherty sage therapeutics

Did you know?

Web13 mei 2024 · Jim Doherty, Chief Research Officer, Sage Therapeutics Mike Quirk, Vice President, Pharmacology, Sage Therapeutics Aaron Koenig, Executive Medical … Web16 sep. 2024 · Cecchi, Marco and Adachi, Megumi and Basile, Anthony and Buhl, Derek and Chadchankar, Heramb and Christensen, Søren and Christian, Edward and Doherty, Jim and Fadem, KC and Farley, Brandon and Forman, Mark and Honda, Sokichi and Johannesen, Jason and Kinon, Bruce and Klamer, Daniel and Michael, Marino and …

Web30 sep. 2024 · Jim Doherty, Ph.D., assumed the role of Chief Development Officer. Jim will continue to drive expansion and acceleration of Sage’s development programs and lead the Research and Development Leadership Team. ... contact Sage Therapeutics, Inc. at 1-844-4-SAGERX (1-844-472-4379) ... Web1 mrt. 2024 · On average, Sage Therapeutics Inc executives and independent directors trade stock every 30 days with the average trade being worth of $1,484,590. The most recent stock trade was executed by Kimi Iguchi on 21 February 2024, trading 1,000 units of SAGE stock currently worth $1,360.

Web13 mei 2024 · Jim Doherty, Chief Research Officer, Sage Therapeutics Mike Quirk, Vice President, Pharmacology, Sage Therapeutics Aaron Koenig, Executive Medical Director, Early Development, Sage Therapeutics WebView the business profile and contact info for Jim Doherty, Chief Development Officer at Sage Therapeutics, Inc. in Massachusetts, US Dynamic search and list-building …

WebChief Development Officer @ Sage Therapeutics; Chief Research Officer @ Sage Therapeutics; Senior Vice President, Research @ Sage Therapeutics; see more Vice …

WebTotal downloads of all papers by Jim Doherty. If you need immediate assistance, call 877-SSRNHelp (877 777 6435) in the United States, or +1 212 448 2500 outside of the … patrick lavardeWeb13 apr. 2024 · Sage Therapeutics, Inc., presented data from the Phase 2 LUMINARY Study that showed SAGE-718, a first-in-class, oral, positive allosteric modulator of the NMDA receptor, was generally well-tolerated and associated with improvement on multiple tests of executive performance and learning and memory in patients with mild cognitive … patrick lavarrepatrick lattner evansville indianaWeb6 sep. 2024 · Jim Doherty Chief development officer, Sage Therapeutics “While there have been many amazing advances, we are just at the beginning of a new age in neurology in which exciting new treatments will potentially be discovered,” Doherty says. Here, Doherty discusses why Sage’s work is critical now more than ever and his key … patrick laverdantWeb3 mei 2024 · Sage Therapeutics, Inc. (NASDAQ:SAGE) Q1 2024 Earnings Conference Call May 3, 2024 8:00 AM ET. Company Participants. Helen Rubinstein - Investor Relations. … patrick lavellaWeb2 nov. 2024 · Jim Doherty -- Chief Research Officer Thanks, Barry, and good morning, everyone. In 2024, we have made important advancements across our three brain health franchises, including our early stage... patrick latronWeb16 feb. 2024 · Sage Therapeutics, Inc. (NASDAQ:NASDAQ:SAGE) Q4 2024 Earnings Conference Call February 16, 2024 8:00 AM ETCompany ParticipantsHelen Rubinstein ... Jim Doherty. Absolutely, Barry. patrick lavette